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 ABSTRACT 
Previous studies have demonstrated carotid body (CB) activity is increased in a high fat diet 
(HF) induced model of insulin resistance (IR), and carotid sinus nerve resection prevents 
this and the associated hypertension (HT). The chronic intermittent hypoxia (CIH) of 
obstructive sleep apnoea also results in HT. We therefore hypothesised the combination of 
HF induced IR and CIH would result in further increase of CB activity and HT. Effects of HF 
and CIH on cardiorespiratory parameters, IR, CB activity and sympathetic output were 
assessed in anaesthetised Wistar rats. HF rats developed obesity, IR and ventricular 
hypertrophy, with CIH reducing weight gain, but not affecting IR or hypertrophy. Mean 
arterial blood pressure (MABP) in HF rats tended to be increased by 12±3mmHg, with 
systolic BP significantly increased. In combination with CIH, MABP tended to be increased 
by 10±3mmHg, with systolic BP not significantly increased. Treatment groups showed no 
increased ventilatory drive or sympathetic activity. In conclusion, HF induces obesity, IR 
and ventricular hypertrophy, however did not result in significant MABP increase. In 
combination with CIH, obesity is reduced however IR, hypertrophy and MABP do not 
appear to be affected. Also neither HF diet nor CIH cause increased CB or sympathetic 
activity. 
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INTRODUCTION 
Obstructive Sleep Apnoea Syndrome 
Obstructive sleep apnoea syndrome (OSA) is a common disorder affecting approximately 
2% middle aged women and 4% middle aged men (Cooper et al 2004).  OSA is 
characterised by apnoeic episodes due to recurrent upper airway collapse of the pharynx 
during sleep, resulting in arousals, sleep fragmentation and oxyhaemoglobin desaturation 
(Ong et al 2013, Malhotra and White 2002, and Cooper et al 2004).  The pharyngeal dilator 
muscles and surrounding soft tissues are important in maintaining pharyngeal patency as 
there is a lack of bony support in the region behind the tongue and soft palate.  Airway 
collapsibility (see fig.1) is promoted by a combination of intraluminal negative pressures 
produced upon inspiration by the diaphragm and extra-luminal forces applied by the bony 
structures and tissue surrounding the airway (Ong et al 2013).  Opposing the collapsing 
forces are the pharyngeal dilator muscles action and the longitudinal traction on the 
airway from lung inflation (Ong et al 2013).  Change in activation of these dilator muscles 
with the onset of sleep is thought to be the pivotal event in susceptible individuals. 
The apnoeic events caused by the obstructed inspiratory flow are associated with hypoxia 
and hypercapnia, which stimulate the carotid body (CB) chemoreceptors, and can vary in 
frequency from 5-60+ an hour (Cooper et al 2004, Polotsky et al 2003).  Once an apnoea 
develops arousal and strong inspiratory efforts are necessary to stop the event, as 
pharyngeal patency is only restored by sympathetic nervous system (NS) activation upon 
arousal (Cooper et al 2004).  Patients therefore repeatedly arouse from sleep throughout 
the night (Polotsky et al 2003, Nacher et al 2007).  The stimulus of arousal is debated with 
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it suggested to be increased respiratory effort alone or some combination with hypoxia or 
hypercapnia as the cause (Malhotra and White 2002). 
 
Figure 1:   The balance of forces. Pharyngeal collapse is promoted by inspiratory negative 
pressure and extraluminal positive pressure.  Airway patency is maintained by upper airway 
dilator muscles and increased lung volume.  Figure adapted from Malhotra and White 2002. 
 
The ongoing respiratory effort leads to considerable decrease in intrathoracic pressure, 
these negative pressures contribute to cardiac preload and left ventricular (LV) afterload.  
At the end of an apopnea, the increased stroke volume (preload) along with the 
vasoconstricted circulation (due to sympathetic activation) can lead to repetitive intense 
acute increases in systemic blood pressure (BP). 
Chronic consequences of OSA are sustained periods of high BP.  This observation is 
supported by animal investigations and the mechanisms probably include sustained 
sympathetic excitation, oxidative stress and release of endothelin-1 (Thomas 2011).  This 
sustained hypertension (HT) occurs in 40-60% OSA patients and is independent of common 
risk factors such as obesity, and may also be linked to subsequent myocardial infarction, 
cerebrovascular events and congestive heart failure (Cooper et al 2004). 
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The apnoea-hypopnea index (AHI) is a measure of the severity of OSA.  Apnoeas are 
defined as a minimum 10s cessation of airflow, and based on the absence or presence of 
respiratory effort, are classified as central or obstructive respectively.  Hypopneas are 
defined as including one of three features: substantial (>50%) airflow reduction, moderate 
(<50%) airflow reduction with desaturation (>3%) and moderate (<50%) airflow reduction 
with electroencephalographic evidence of arousal (Malhotra and White 2002).  The 
statistics about prevalence vary depending on the definition used.  Previously OSA was 
defined as increased AHI and symptoms such as excessive daytime sleepiness, but because 
of the increased cardiovascular risk many classify non-sleepy patients with high AHI as 
having the disease (Malhotra and White 2002). 
The most important risk factor for OSA is obesity as 70% patients with the disorder are 
obese.  OSA prevalence is rising as a result of obesity reaching epidemic proportions in 
developed countries.  This undoubtedly makes OSA an increasingly important public health 
problem, with obesity the only major reversible risk factor.  Despite this relationship with 
obesity the underlying mechanism is unclear with it probably due to a reduction in 
pharyngeal airway size with increased weight (Arias et al 2005, Malhotra and White 2002). 
Obesity 
OSA and obesity both share multiple pathophysiological mechanisms such as endothelial 
dysfunction, insulin resistance (IR), hyperleptinaemia, systemic inflammation and 
impairment of baroreflex or hyperactivity of sympathetic NS (Arias et al 2005). 
Obesity’s role in OSA pathogenesis is thought to include fat deposition altering upper 
airway structure and function that promotes collapsibility, reduction in resting lung volume 
and disturbance of central breathing control mechanisms (Ong et al 2013, Arias et al 2005).  
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Lung inflation applies longitudinal traction on the larynx and trachea reducing collapsibility 
by increasing airway rigidity.  Obesity, particularly central, lessens this effect as fat 
deposition in the thorax decreases lung compliance and increases the airways passive 
collapsibility and predisposes to respiratory control system instability (Ong et al 2013).  
Most obese subjects have elevated leptin levels, due to adipocyte mass, which may also 
have a pathogenic role.  Leptin acts as a neurohumoral modulator of central respiratory 
control mechanisms and the development of leptin resistance, due to hyperleptinaemia, is 
associated with a reduction in respiratory drive and hypercapnic response (Campo et al 
2007, Malli et al 2010, O’Donnell et al 2000).  OSA itself is also associated with raised leptin 
levels and has been hypothesised as a leptin resistant state (Malli et al 2010, Phillips et al 
2000). 
Obesity is also linked to a number of other comorbidities such as those which make up the 
metabolic syndrome.  A group of interrelated disorders metabolic syndrome includes 
obesity, glucose intolerance, IR and HT, which amongst others significantly increase 
cardiovascular risk (Eckel et al 2005, Guo 2014).  The association of IR and HT with obesity 
is thought to be due to increased CB activity causing elevation of sympathetic NA, as 
cartotid sinus nerve (CSN) resection has been shown to prevent their development (Ribeiro 
et al 2013). 
Glucoregulation and Insulin Resistance 
For most tissues, glucose is the primary source of energy, and plasma glucose needs to be 
regulated closely as hyper and hypoglycaemia can have severe consequences (Yeo and 
Sawdon 2013).  Many factors can affect glucose delivery and removal from the blood, 
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including dietary carbohydrate and fat, circulating free fatty acids, exercise, hypoxia and 
hormone action (Casey 2004.) Hormone action is the main regulator of plasma glucose (see 
fig.2), with a number of hormones responding to changes in plasma glucose concentration.  
The most important hormone is insulin which promotes plasma glucose clearance, 
whereas a number of other hormones, glucagon, growth hormone and catecholamines, 
stimulate the release of glucose into the plasma (Casey 2004). 
 
Figure 2:   Hormonal control of plasma glucose. Figure adapted form Casey 2004 
 
Insulin is secreted from β cells of the islets of Langerhans in the pancreas in response to 
elevated blood glucose (Casey 2004, Yeo and Sawdon 2013).  It acts to promote glucose 
uptake into skeletal muscle, liver and adipose tissue while at the same time promoting 
glucoses conversion to glycogen, the major storage form of glucose.  Insulin also dampens 
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down gluconeogenesis activity (the metabolic pathways leading to the production of 
glucose).  The net result of these actions is a decrease in plasma glucose (Casey 2004, Yeo 
and Sawdon 2013). 
In response to low plasma glucose levels glucagon is secreted from the α cells of the 
pancreas.  Glucagon increases glycogen breakdown into glucose (glycogenolysis), which 
can then be directly exported to the blood from the liver.  Glucagon also acts to reduce 
glucose demand by inhibition of metabolic pathways (Yeo and Sawdon 2013).   
Catecholamine hormones (adrenaline and noradrenaline) are secreted from the adrenal 
medulla and inhibit insulin secretion and help to preserve plasma glucose levels.  
Adrenaline secretion leads to activation of glycogenolysis in muscle and liver.  Hepatic 
gluconeogenesis, the conversion of hepatic glucose-6-phosphate to glucose and its release 
into the circulation is also enhanced by increased catecholamine levels (Casey 2004, Yeo 
and Sawdon 2013).  The Pancreatic α cells are additionally under the control of the 
sympathoadrenal response, with adrenaline secreted after a fall in glucose stimulating an 
increase in levels of glucagon release (Yeo and Sawdon 2013). 
Glucose transport across membranes is facilitated by the GLUT family of glucose 
transporters present on the surface of cells.  GLUT-1 is constitutively expressed and 
responsible for basal glucose level, and its expression is not affected by hormone action.  
GLUT-4 is however affected, with high insulin concentrations up regulating its expression in 
skeletal muscle and adipose tissue, resulting in increased glucose uptake by tissues (Yeo 
and Sawdon 2013).  This action is insulin’s principle method of promoting glucose 
clearance from the blood (Yeo and Sawdon 2013). 
15 
Skeletal muscle is the most important store for glucose in the fed state, with its sensitivity 
important for maintaining glycaemic homeostasis (Casey 2004, Yeo and Sawdon 2013).  
Insulin resistance is when insulin induced glucose uptake is impaired in insulin-sensitive 
tissue, meaning a higher than normal insulin concentration is needed to achieve a normal 
metabolic response (El Zayadi 2010, Ye 2013).  Insulin resistance can be peripheral or 
hepatic, with peripheral referring to diminished insulin-mediated uptake by skeletal 
muscle, chiefly due to impairment of GLUT-4 expression (El Zayadi 2010). 
Wistar rats fed hyper-caloric diets produce similar changes in body weight, BP and insulin 
de-sensitivity as those seen in humans (Ballal et al 2010, Conde et al 2012, Ribeiro et al 
2013), and as such are a model of diet-induced IR and HT.  In this high fat model increased 
CB chemoreceptor activity is observed.  The CB is known to activate the sympathetic NS, a 
well-known pathophysiological mechanism of HT (Ribiero et al 2013).  Elevated 
sympathetic NA also contributes to skeletal muscle IR and impaired glucose tolerance by 
sympathetic mediated lipolysis and increased arterial pressure (Ribiero et al 2013).  In rats 
carotid sinus nerve (CSN) resection completely prevents diet induced HT and IR, suggesting 
obesity is a related factor of CB stimulation, and CB activation is an underlying mechanism 
of dietary induced HT (Ribeiro et al 2013). 
Recognised OSA subjects have central obesity and other features of the metabolic 
syndrome which include IR, glucose intolerance and HT (Ip et al 2002).  However findings 
suggest OSA is independently associated with IR and HT (Ip et al 2002).  Both HT and IR are 
developed by lean-sleep apnoea patients demonstrating their association with CIH in the 
absence of visceral obesity and the fundamental role it is proposed to play in the 
pathophysiology (Ribiero et al 2013). 
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Intravenous glucose tolerance test (GTT) is a robust and reproducible technique allowing 
the assessment of insulin release to a glucose load (Frangiousdakis et al 2008).  Animals are 
given a set glucose load intravenously, with blood samples taken over time points, to allow 
blood glucose and plasma insulin level monitoring. 
Hypertension 
A dose-response relationship between OSA and HT has been demonstrated, with greater 
OSA severity resulting in increased risk HT and a greater elevation in BP (Baguet et al 
2009).  The exact mechanism of OSA induced HT is not clear, with multiple mechanisms 
thought to contribute to the elevation of BP (see fig.3) (Schulz et al 2014, Qian et al 2012). 
OSA patients present haemodynamic oscillations during the night; heart rate (HR), BP and 
cardiac output (CO) vary due to respiratory events and changes in alertness.  These 
cardiovascular responses are the outcome of four stimuli: hypoxaemia, hypercapnia, 
changes in intrathoracic pressure and microarousals (Baguet et al 2009).  The dipping 
phenomenon, a fall in BP of approximately 10%, that occurs at night is also absent in 
apnoeic patients (Baguet et al 2009).  With episodic nightly hypoxia observed to result in 
elevation of diurnal BP (Fletcher et al 1992a).  The sustained HT can be attributed to the 
hypoxia and not changes in arousal as in the canine model upper airway obstruction leads 
to sustained increase in BP; however sleep fragmentation causes only acute HT peaks 
(Baguet et al 2009).  It has also been put forward that repetitive intermittent hypoxia (IH) 
may be a major cause of hypertension even in some patients labelled essential 
hypertensive (Fletcher 2001). 
Human and animal studies suggest sympathetic over-activity is the major 
pathophysiological mechanism behind the chronic arterial HT associated with OSA (Baguet 
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et al 2009, Schulz et al 2014).  Chemical sympathectomy, using a neurotoxin to poison 
peripheral sympathetic synapses, resulted in no change in BP in IH exposed rats (Fletcher 
2001).  Also increased sympathetic activity causes elevated peripheral arterial resistance 
and explains the predominately diastolic nature of OSA HT (Baguet et al 2009).   
The sympathetic NS has a dominant role in cardiovascular control.  Sympathetic discharge 
can involve multiple regional effectors and cause dispersed responses (Thomas 2011).  Its 
effects increase cardiac rate, contractility, vasoconstriction, release of adrenal 
catecholamines and activation of the renin angiotensin aldosterone system (RAAS) 
(Thomas 2011).  Sympathetic control of arteriolar resistance regulates regional blood flow.  
Arterioles are chief contributors to total peripheral resistance (TPR) and as such 
sympathetic control is a principle regulator systemic BP (BP = CO x TPR) (Thomas 2011). 
Sympathetic NS also innervates the adrenal medulla, causing synthesis and release of 
adrenaline and noradrenaline.  These circulating catecholamines have vascular effects; 
noradrenaline causes vasoconstriction and adrenaline at physiological levels induces 
vasodilation in skeletal muscle and the liver (Thomas 2011). 
Chronic intermittent hypoxia (CIH) induced HT is prevented by CB denervation, which 
suggests intact chemoreceptors are needed for arterial pressure to increase (Kohler and 
Stradling 2013).  Hypercapnia is itself a sympathetic stimulation factor (Baguet et al 2009) 
and studies show hyperoxia suppresses sympathetic stimulation and BP variations during 
apnoeas (Baguet et al 2009). 
In addition to the sympathetic over-activity, endothelial dysfunction and oxidative stress 
are thought to play a role. During OSA there are changes in endothelial function 
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Figure 3:   OSA related mechanisms of hypertension. Figure adapted from Baguet et al 
2009. 
 
 (independent of obesity or atherosclerosis risk factors) that cause decreased vasodilation 
and vasoconstriction.  This dysfunction is caused by sympathetic activation, systemic 
inflammation and oxidative stress usually present in apnoeic patients (Baguet et al 2009). 
The desaturation re-oxygenation that occurs during CIH leads to the production of reactive 
oxygen species (ROS).  Increased ROS activate leukocytes producing systemic 
inflammation, generating vascular endothelium damage and dysfunction promoting 
arterial HT (Schulz et al 2014, Baguet et al 2009, Qian et al 2012).  Oxidative stress causes 
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vasoconstriction by multiple mechanisms; activation of angiotensin II, increased generation 
of endothelin-1 (Baguet et al 2009) and also by reducing the bioavailability of the 
endothelial-derived vasodilator nitric oxide (NO) (Schulz et al 2014).  The NADPH oxidases 
(NOX) are major ROS generating enzymes.  NOX derived ROS decrease NO bioavailability 
causing loss of vasodilator tone and arterial hypertension (Schulz et al 2014).  The glomus 
cells of the CB also have enhanced NOX2 activity under CIH, the transcription factor HIF-1α 
activates NOX2 and causes a subsequent ROS release and increased sympathetic activity, 
elevating BP (see fig.4) (Schulz et al 2014).  It has been shown in animals and humans that 
IH increases circulating endothelin-1 levels, a powerful vasoconstrictor (Baguet et al 2009). 
Rats exposed to IH also show over activity of the adrenergic and renin-angiotensin systems 
contribute to the chronic BP elevations (Fletcher 2001).  The increase in BP caused by CIH 
can be prevented by CB denervation, sympathetic nerve ablation, renal sympathectomy 
and angiotensin II receptor blockade (Fletcher 2001). 
Sympathetic and Parasympathetic Nervous System Cardiovascular Control  
Obesity related HT and IR and OSA related HT are all thought to be caused by increased 
sympathetic activity.  Subjects with OSA have altered chemoreceptor reflexes and 
baroreflex control, and the periodic nightly sympathetic activation evolves into a rise in 
daytime level sympathetic NS activity when subjects are breathing normally (Thomas 
2011). 
The arterial baroreflex is a negative feedback system for BP around an internal set point.  
This sympathoinhibitory reflex is stimulated by acute changes in arterial BP sensed by 
baroreceptors in the carotid sinus and aortic arch, which adjust CO and vascular resistance 
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to return BP to its set point (Thomas 2011).  Increased BP causes an increase in 
baroreceptor discharge, resulting in reflex inhibition of sympathetic outflow to the heart 
and vasculature and activation of vagal parasympathetic outflow to the heart.  This causes 
decreases in vascular resistance, stroke volume and HR and therefore reduces BP (Thomas 
2011).  A decrease in BP has the opposite effect evoking reflex increases in peripheral 
resistance, stroke volume and HR by increasing sympathetic outflow, to the heart and 
vasculature, and reducing vagal parasympathetic activity to the heart, to restore BP 
(Thomas 2011).  Chronic resetting can occur, with the reflex operating around a new set 
point (Thomas 2011).  Asphyxic gas breathing has been shown to reset the vascular 
resistance component of carotid baroreflex at a higher pressure (Cooper et al 2004). 
The reason for HT development may be related to baroreceptor resetting occurring as 
result of repeated nightly HT (Cooper et al 2004).  Resetting of the sympathetic baroreflex 
control, not impairment of sensitivity is associated with the onset of CIH induced 
hypertension (Kohler and Stradling 2013).  Rats exposed to CIH showed increases in BP 
before any alteration in sensitivity is observed (Kohler and Stradling 2013). 
The Carotid Body Chemoreceptors 
Overstimulation of the carotid body is thought to be the chief mechanism involved in the 
increase in sympathetic activity with obesity and OSA (Ribeiro et al 2013).  Located 
bilaterally in the neck CBs are classically activated by hypoxia and hypercapnia increasing 
their sensory nerves, the CSN, action potential frequency (Kumar and Prabhakar 2012).  
Integration of the CSN occurs in the brain stem, where it induces respiratory reflexes 
directed at normalising altered blood gases.  This is mainly achieved by hyperventilation, 
and BP and cardiac performance regulation via sympathetic NA (Ribeiro et al 2013). 
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Recurrent apnoea patients exhibit augmented hypoxic ventilator response (HVR) which is 
attributed to enhanced sensitivity of peripheral chemoreceptors (see fig 4).  This is 
consistent with the finding of a more pronounced ventilatory depression to hyperoxic 
challenge (Dejours test) in OSA patients compared to controls (Kumar and Prabhakar 
2012).  The Dejours test is a measure of peripheral chemoreceptor sensitivity (Kumar and 
Prabhakar 2012) and involves breathing 100% O2 for a short period.  During the early 
stages of apnoea syndrome carotid body sensitization may be beneficial in aiding to 
maintain oxygenation via HVR augmentation and BP increases.  If untreated however this 
augmented hypoxic sensitivity may result in unstable breathing and an increased number 
of apnoeas (Kumar and Prabhakar 2012). 
Table 1.  Stimuli causing carotid body discharge and reflex consequences 
(adapted from Kumar and Bin-Jaliah 2007) 
Adequate Stimuli of the 
Carotid Body 
Reflexes Produced by Carotid Body Activation 
Hypoxia Hyperventilation 
Hypercapnia Cardiovascular Responses : 
Acidosis Primary:   Bradycardia 
↓ Cardiac Output 
↓ Stroke Volume 
Peripheral Vasoconstriction 
Hyperkalaemia 
Hyperthermia 
Catecholamines Secondary (to Hyperventilation): 
Tachycardia 
Renal Vasoconstriction 
Peripheral Vasodilation 
Angiotensin II 
ADH 
Adenosine Other Sympathoexcitatory Responses: 
Endothelins ↑ Renal Sympathetic NA 
↑ Muscle Sympathetic NA 
Augmentation Pituitary-Adrenocortical Axis 
Augmentation Adrenomedullary 
Catecholamine Secretion 
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Glomectomised sleep apnoea patients do not develop HT.  Also IH exposed rats develop HT 
similar to recurrent apnea patients with sectioning of sinus nerve preventing the response, 
both provide indirect evidence of altered CB function in humans and rodents exposed IH 
(Lesseke et al 1997, Kumar and Prabhakar 2012). 
Activation of the carotid body reflexly activates the sympathetic nervous system.  CIH-
induced sensory long-term facilitation (LTF) contributes to the continuing sympathetic NA 
elevation observed in recurrent apnoea patients (Kumar and Prabhakar 2012). 
Hypoxia is still considered the most significant peripheral chemostimulus, but it is 
becoming increasingly evident the CB can transduce many other stimuli: arterial PCO2 and 
pH, also blood potassium concentration, temperature and osmolarity, as well as potentially 
blood glucose levels (see table 1) (Kumar and Bin-Jaliah 2007).  However the question 
remains, is there one transduction process which senses all the stimuli or distinct stimuli 
sensors with common downstream transduction pathways (Kumar and Bin-Jaliah 2007).  
Osmolarity and hypoglycaemia appear to be sensed independently of the hypoxia sensing 
mechanism but both mechanisms converge at type 1 cell membrane depolarisation or 
Ca2+-dependent neurosecretion (Kumar and Bin-Jaliah 2007).  The CB’s afferent neural 
output does not appear to distinguish between stimuli but rather only grades for intensity 
to induce cardiorespiratory and endocrine reflexes (Kumar and Bin-Jaliah 2007). 
In addition to its role in control of ventilation the CB has been proposed as being able to 
sense glucose and thus implicated in the control of energy homeostasis (Ribiero et al 
2013).  Although some central neurons can sense glucose concentration, peripheral 
glucose sensors outside the brain are needed for the counter-regulatory responses.  The 
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Figure 4:   Effect of CIH on the cardiorespiratory system.  Mechanisms and consequences of 
CIH induced changes in carotid body on the cardiorespiratory system.  Figure adapted from 
Kumar and Prahbakar 2012. 
 
CB’s location and characteristics (high blood flow and metabolic rate) would enable it to 
detect rapid glycaemic changes (Lopez-Barneo 2003).  However the CBs role in glucose 
sensing is yet to be established definitively, with different preparations observing different 
results.  In CB thin slices hypoglycaemia has been shown to induce a secretory response 
similar to hypoxia (Pardel et al 2002). However Bin-Jaliah (2004) reported insulin induced 
hypoglycaemia resulted in increased ventilation in vivo, but in vitro hypoglycaemia had no 
effect on CB discharge frequency. 
Though there is increasing evidence that suggests it may play a part in initiation of the 
reflex counter-regulatory responses along with the pancreas, liver and hepatic portal vein 
(Kumar and Bin-Jaliah 2007).  It has been shown that CB resection in dogs impairs the 
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counter regulatory responses to insulin-induced mild hypoglycaemia (Lopez-Barneo 2003).  
CSN resection in rats also showed decreased insulin sensitivity (Ribeiro et al 2013).  This 
suggests CBs contribute to the maintenance of glucose homeostasis.   
A new role for hyperinsulinaemia as a stimulus of CB over activation has also been 
proposed (Ribiero et al 2013).  Increased insulin levels trigger the CB activating the 
sympathetic NS and initiating a cycle that worsens peripheral insulin action, impairs B-cell 
function and causes systemic HT (Ribiero et al 2013). 
Animal Models of Obstructive Sleep Apnoea 
To advance the understanding of sleep apnoea and target patients who are at greatest risk 
of morbidities with treatment, it is necessary to identify the interactions between 
physiological variables.  However it is difficult to undertake in-depth study into the chronic 
effects and pathophysiological mechanisms of the various factors (fluctuations in O2, CO2, 
behavioural state, respiratory drive, ventilatory effort and upper airway intraluminal 
pressures) influencing the course of apnoeas in humans (Farre et al 2007, Nacher et al 
2007).  The difficulty arises due to a number of confounding variables, such as those 
embodying the metabolic syndrome, that are associated with OSA and also because the 
chronic cardiovascular changes take many years to manifest (Fletcher 2001). 
Due to these difficulties animal models mimicking the characteristic recurrent upper 
airway obstructions of OSA are useful in eliciting the pathophysiological mechanisms of the 
syndrome (Nacher et al 2007).  Animal models avoid the associated comorbidities, and 
develop OSA’s chronic pathophysiology on a much shorter time scale, as well as enable the 
use of invasive techniques and measurements under well-controlled experimental 
conditions that are not possible in humans (Farre et al 2007).   
25 
There are many different animal models available for the study of OSA.  Dog models of 
OSA have been used, as well as miniature pigs which have been used as an obesity induced 
model (Lonergan et al 1998, Kimoff et al 1997).  Mice and rats are also used in research as 
rodents have many similarities in BP control and cardiovascular responses with humans 
(Fletcher 2001).  Rodents are a relatively cheap model of OSA and allow the different 
properties to be easily copied artificially. 
Airway obstruction can be applied indirectly avoiding the need to manipulate the animal’s 
airway by an occluding head chamber.  As the animal’s airway is not actually occluded it is 
able to breathe a small airflow associated with pressure changes induced by muscle effort 
exerted on low compliance gas chamber (Farre et al 2007).   
Another model involves performing a tracheotomy with a cannula containing an inflatable 
balloon inside a rigid Teflon tube implanted in trachea.  Inflation of the balloon allows the 
induction of an apnoea without inducing pain (Schoorlemmer et al 2011).  The apnoea can 
last up to 16 seconds during REM sleep without causing the rat to wake.  The use of the 
balloon also allows apnoeas to be induced at a fixed point in the respiratory cycle and elicit 
cardiorespiratory responses similar to humans (Schoorlemmer et al 2011). 
However the downside of these models is the rats’ movement has to be restricted, which 
even after their familiarisation with the setup is a source of stress.  This stress can cause 
reduced weight gain and elevated plasma corticosterone levels (Farre et al 2007). 
Commonly the mechanisms of sleep apnoea are studied in conscious rats or mice exposed 
to IH, as it avoids movement restriction (Schoorlemmer et al 2011).  Hypoxic chambers can 
contain single or multiple animals, with pure nitrogen gas used to lower the O2 
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concentration to 3-5%.  The IH can be delivered in various cycle length durations (hours) 
and number of days or weeks (Fletcher 2001). 
IH replicates many features of OSA but not all.  IH differs to OSA as it does not provoke the 
characteristic respiratory effort, therefore not permitting study of the potential 
cardiovascular consequences of strenuous breathing against an obstructed airway (Farre et 
al 2007).  Strenuous breathing causes alteration of cardiac pre and afterload which may 
contribute to OSA pathology (Schoorlemmer et al 2011) and the mechanical stimulus acts 
as an immune challenge causing inflammation and metabolic responses that may be 
significant (Farre et al 2007).  IH also does not induce the hypercapnia observed during 
apnoea, although it can be replicated by creating a hypoxic, hypercapnic atmosphere to 
breathe (Schoorlemmer et al 2011).  Lastly respiration usually becomes blocked during 
sleep in OSA and then resumes on awakening, this is not easily replicated with the IH 
model (Schoorlemmer et al 2011).  However hypoxia is the most important factor in the 
development of HT, with it demonstrated that CIH alone can cause persistent elevation of 
MABP (Fletcher et al 1992a, Fletcher 2001).   
CIH models allow the manipulation of the number of apnoeas per hour as well as the 
duration of each apnoea.  This ability to alter the severity of CIH is something 
experimenters have taken full advantage of with cycle lengths used varying from <10 to 
>60 per hour, and apnoea duration from <5 to >15 seconds.  The severity of the induced 
apnoea also varies with some using oxygen concentrations as low as 3% and others as high 
as 10% (Crossland et al 2013).  The total duration used also differs with some studies using 
as little as 3 hours and others 6 or 8 hours a day (Nacher et al 2007, Farre et al 2007).  All 
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these variations in the CIH model may actually be beneficial as it can be used to reflect the 
various severities of OSA found in the human population. 
The model of CIH used in this study has not been used before, it was chosen with the aim 
of mimicking the early stages of OSA. The protocol involves a low number of apnoeas, 6 
per hour, which is above the level for diagnosis with mild OSA, ≥5 per hour, but below the 
level recommended for treatment, ≥15 per hour.  During the protocol the oxygen 
concentration decreases to 5-6% over 90 seconds before increasing back to normoxic 
levels over a further 90 seconds.  Rats were placed in the hypoxic chamber for 8 hours 
every day during their normal sleep cycle for 2 weeks.  This duration was chosen as the 
normal sleep period for humans and rodents is between 6-8 hours every a day (Fletcher 
2001). 
Aims and Hypotheses 
Given evidence that CB activity is increased in a HF diet induced model of IR and that CSN 
resection prevents this and the associated increases in BP, and evidence that the CIH of 
OSA results in HT that can be prevented by CSN resection, It is hypothesised that the 
combination of HF diet induced IR and CIH will result in greater up regulation of CB activity 
and result in a more severe HT. 
The aims of this study are: 
1. To assess the effect of HF and HF+CIH on baseline cardiovascular and respiratory 
variables. 
2. To assess the effect of HF and HF+CIH on glucose tolerance and insulin sensitivity. 
3. To assess the effect of HF and HF+CIH on CB function with use of the Dejours test. 
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4. To assess the effect of HF and HF+CIH on vascular response to sympathetic 
stimulation. 
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METHODS 
All experiments were approved under the Animals (Scientific Procedures) Act 1986. 
Animals  
All experiments were carried out on 9 week old male Wistar rats.  Animals were obtained 
from Charles River Laboratories and housed 3 animals per cage, in the Biomedical Services 
Unit, University of Birmingham.  Animals were allowed 1 week acclimatisation before 
experiments.  Animals’ weight, food and water intake were all monitored twice weekly 
following acclimatisation.  Food and water intake was calculated as a third of the total cage 
consumption, with all animals assumed to consume the same amount. 
 
Figure 5: Diet Timeline for control, HF and HF+CIH groups. 
 
Three groups of animals were used in this study (see fig.5).  Control animals (weight 
353±7g) were fed a normal diet of standard laboratory rat chow (3.9Kcal.g-1) containing 
14% protein, 2.5% fat and 6% fibre (EURdent Diet 14%, LabDiet).  The high fat group (HF 
group) animals were fed on the Western diet (4.63Kcal.g-1) containing 17.5% protein, 21% 
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fat and 3.5% fibre (Special Diet Services, LBS Biotech) for 4 weeks (weight 440±14g).  The 
high fat intermittent hypoxia group (HF+CIH group) animals were fed Western diet for 4 
weeks with the final 2 weeks spent in a hypoxia chamber (weight 418±8g).  
HF+CIH animals spent 8 hours a day in the hypoxia chamber (OxyCycler, BioSpherix, see 
fig.6A).  The chamber undergoes 6 cycles every hour, with O2 decreasing from 20-21% 
down to between 5-6% over 90 seconds and then increases back up to 20-21% over a 
further 90 seconds.  There is a then a 7 minute break between cycles (see fig.6B).  The 
decrease in O2 is achieved by the introduction of nitrogen gas into the chamber, with the 
increase in O2 due to the reintroduction of O2. 
All animals were fasted with water and restricted food overnight before surgery.  10g of 
food was given the day before experiments to ensure animals were fasted from 
approximately midnight until surgery the following morning. 
Surgery 
All experiments were conducted in vivo with animals under terminal anaesthesia.  
Anaesthesia was induced by inhalation of IsoFlo (100% isoflurane, National Ventinary 
Supplies) 3-4% with an oxygen flow of 4L.min-1 using a Fluovac anaesthesia system.  The 
animal was placed in the induction chamber until anaesthetised, then moved to the 
surgical bench.  Inhalation anaesthesia was continued through a tube placed over the 
animals head.  The depth of anaesthesia was monitored by looking at the animal’s 
ventilation and the pedal withdrawal reflex test.  Once anaesthesia was deep enough the 
right jugular vein was cannulated to allow anaesthesia to be switched to and maintained 
by intravenous (IV) infusion of Alfaxan anaesthetic.  The Alfaxan (10mg.ml-1 alfaxalone, 
National Vetinary Supplies) was diluted 1:1 with saline before infusion.  The inhalation  
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Figure 6:  A: Picture of hypoxic chamber (taken from website; http://www.biotech-
europe.eu/files/pdf/Animal%20Chamber.pdf) and B: Example of CIH chamber trace  
  
A 
B 
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anaesthetic was stopped once the jugular vein was cannulated, the animal was then 
allowed to breath off the inhalation anaesthetic while small boluses of Alfaxan were given, 
this was to prevent an anaesthetic overdose. 
Once the inhalation anaesthetic had been breathed off Alfaxan was given by automated 
infusion pump (Perfusor, Secura).  Infusion rate was set between 1.5-2.5 ml.hr-1 and could 
be raised or lowered as required; IV boluses could also be given when needed. 
The trachea was then isolated and a trachea tube was inserted through an incision made 
between the cartilage rings.  This tube allowed the airway to remain clear and the animal’s 
respiratory parameters to be monitored throughout the experiment.  Cannulae filled with 
heparinised saline (0.1ml heparin in 25ml 0.9% saline) were also inserted in the left 
brachial artery, left femoral vein and left femoral artery for BP measurement, IV infusion 
and taking blood samples respectively.  The right femoral artery was also isolated to allow 
measurement of blood flow. 
Following the cannulations a laparotomy was performed on the animal.  Once inside the 
abdominal cavity the internal organs were gently moved aside and the tissue blunt 
dissected to expose the vena cava.  The vena cava was then freed from the surrounding 
connective tissue and moved to expose the sympathetic chain underneath.  The 
sympathetic chain was then freed and silver-wire electrodes were then placed around the 
right lumbar sympathetic chain, between L3 and L4, and fixed in place using silicone 
adhesive (Kwik-Sil, World Precision Instruments) to mechanically fix and electrically isolate 
them.  The animal’s abdominal cavity was then closed using suture. 
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Animal’s core body temperature was monitored and maintained at 37oC throughout the 
experiment using an internal temperature probe and homoeothermic monitor connected 
to a thermostatic blanket (Harvard Apparatus). 
Recording Set Up 
Experimental setup is shown in fig.7.  All signal recording was done using a PowerLab 4/30 
and LabChart software (both AD Instruments).  LabChart was set to sample at 100Hz (100 
measurements per second) to ensure accurate data collection. 
A pressure transducer was attached to the brachial artery cannula to allow arterial blood 
pressure (ABP) to be measured.  A 2-point calibration (0 mmHg and 200 mmHg) was 
performed before being attached.  The two points are outside but close to the expected 
range of recordings to prevent inaccurate extrapolation.  From the raw cyclic ABP signal 
mean arterial BP (MABP) was derived on-line as the average measurement of a cycle.  
Systolic (SBP) and diastolic BP (DBP) were also on-line derived as the maximum and 
minimum of cycles respectively.  Similarly HR was derived as 1 beat per cycle peak from 
the ABP signal. 
A perivascular flow probe (0.7V; Transonic Systems Inc. Ithaca, NY, USA) was placed around 
the right femoral artery and used to record blood flow (FBF).  The probe was attached to 
the PowerLab via a blood flow meter (T206, Transonic Systems Inc.).  Mean blood flow 
(MFBF) was derived as an average of the raw FBF signal.  Femoral vascular resistance (FVR) 
was calculated on-line from the division of ABP by FBF. 
A pneumotac spirometer was attached to the trachea tube allowing the airflow signal to be 
recorded.  From the raw cycle trace the tidal volume (VT) was calculated from the area 
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under the curve, and respiratory frequency derived as one breath per cycle peak.  The 
spirometer was calibrated for tidal volumes between 0 and 5ml before it was attached to 
ensure VT are correctly derived.  A three lead ECG was taken with electrodes attached to 
the animals’ left and right forelimbs and right hind limbs.   
The sympathetic chain electrodes were attached to the PowerLab and stimulated at a 
constant voltage of 2 volts (V).  The chain was stimulated with 60 impulses at two different 
frequencies, 20Hz and 2Hz. 
Glucose infusion was made via the left femoral vein cannula, with all blood samples taken 
from the left femoral artery. 
Protocol 
Glucose Tolerance Test 
Following surgery the anaesthesia was adjusted and the animal was allowed to stabilise for 
approximately 30 minutes.  Baseline blood samples were taken once the recordings had 
stabilized for blood glucose, insulin (~150µl) and haematocrit (20-30 µl).  1ml.kg-1 animal 
weight of 0.5g.ml-1 of glucose was given as an IV bolus followed by 0.5ml of saline with 
arterial blood samples taken at 2, 5, 10, 15 and 30 minute intervals to monitor blood 
glucose and insulin levels. 
Blood glucose was measured using blood glucose strips and a blood glucose monitor 
(Roche Contour XT, Accu-Check Aviva Nano and FreeStyle Optimum) with values given in 
mMol.L-1.  Insulin arterial blood samples were spun in a centrifuge at 10,000RPM for 5min 
to separate out the plasma.  The plasma was then removed and frozen in liquid nitrogen 
and then stored in a -80oC freezer until analysed for insulin content.  Haematocrit was 
measured in duplicate; with arterial blood samples collected in small 40µl heparinised 
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Figure 7:   Experimental setup 
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capillary tubes.  The samples were then centrifuged for 5 minutes at 10,000RPM to 
separate the plasma and red blood cells.  The length of the packed cell volume was then 
measured and calculated as a proportion of the whole sample length.   
Dejours Test 
Dejours tests were performed.  The Dejours test involved giving the animal 100% O2 to 
breathe for 30 seconds, and was repeated five times with suitable time for recovery 
between repeats. 
Sympathetic Stimulation 
The vascular responses to sympathetic stimulation were evoked by stimulation of the 
sympathetic chain at two different frequencies, 20Hz and 2Hz.  The stimulation patterns 
were chosen to compromise the same number of 0.1ms impulses, in a 30 second period.  
The protocol patterns were adapted from previous work by Coney and Marshall (2003).  
Both stimulation protocols consisted of 60 impulses, at a constant voltage of 2V.  The 20Hz 
stimulation consisted of 3 times 20 impulse bursts spaced 10 seconds apart, with the 2Hz 
stimulation consisting of 1 set of 60 impulses. 
At the end of the protocol animals were euthanased using euthatal, with death confirmed 
by cervical dislocation. 
Insulin Quantification 
Plasma samples taken during the GTT at 0, 2 and 30 minutes for control, and 0, 2 and 60 
minutes for HF and HF+CIH groups were analysed for insulin.  Insulin concentration was 
determined using Mercodia Rat Insulin ELISA (10-1250-01, Mercodia AB, Sweden).  
Absorbance values were read at 450nm with insulin concentration (µg.L-1) determined 
from a calibration curve of known insulin concentrations. 
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Tissue Samples 
Tissue samples were obtained from HF and HF+CIH animal groups.  Normal tissue samples 
were obtained from a previous study, with animals fed standard rat chow.  Tissues were 
removed, weighed and frozen using liquid nitrogen.  Samples were then stored at -80oC. 
Skeletal muscle samples were obtained from animal groups, with the right leg tibialis 
anterior (TA), extensor digitorium long (EDL) and soleus muscles all removed, weighed, 
attached to corkboard using OCT and frozen in liquid nitrogen cooled 2-methylbutane 
(sigma). 
The heart was removed, weighed and split into the right free wall, left free wall and 
septum which were weighed and frozen separately in the same way as above, as were 
sections of blood vessels from the aorta and right femoral artery. 
The liver and kidney were also removed along with samples of the perirenal white adipose 
tissue (PWAT) and epididymal white adipose tissue (EWAT).  Samples were weighed, 
wrapped in foil and frozen directly in liquid nitrogen.  Lung and diaphragm tissue samples 
were also frozen in this way. 
Analysis 
Data was taken from LabChart traces and put into a spread sheet before being graphed 
and analysed.  Statistical analysis was carried out using GraphPad Prism software.  All 
values are given as mean ±SEM.  During GTT and insulin quantification values that return to 
baseline before 60 minutes were assumed to continue at that level.   Statistical significance 
was determined by use of Students t test and one way ANOVA with Bonferonni post-hoc 
analysis.  Comparisons were considered significant at P values < 0.05.   
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RESULTS 
Blood Pressure 
Baseline mean arterial pressure (MABP) in the control group was 110±4mmHg.  In both the 
HF and HF+CIH groups MABP was ~10mmHg higher (122±3 and 120±3mmHg respectively), 
however these increases were not significant (see fig.8B and table 2).  There was no 
significant difference between diastolic blood pressure (fig.8D) between control and 
treatment groups however systolic blood pressure (fig.8C) was significantly higher in the 
HF group (control 136±4 and HF 153±4mmHg, P<0.05) but was not in the HF+CIH group 
(149±4mmHg). 
MABP was relatively constant over the protocol with a comparison of MABPs at the start 
and end of the protocol showing no significant difference in control and HF+CIH groups.  A 
significant decrease in MABP was found in the HF group (start 122±3 and end 
117±3mmHg), however this is not a very large or physiologically relevant decrease. 
Heart Rate 
Baseline HR in control group was 427±13BPM (table 2).  HR in the HF and HF+CIH groups 
was ~10 BPM higher (438±13 and 437±9BPM respectively), this increase is however not 
significant (see fig.9). 
Haematocrit 
Haematocrit value for control group was 0.46±0.01.  Both HF and HF+CIH groups also had 
similar values (0.45±0.01 and 0.45±0.01); with no significant difference found between the 
groups (see fig.10).   
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Figure 8:  Effects of HF diet and CIH on baseline arterial blood pressures (mmHg) in control (n=9), HF (n=8) and HF+CIH (n=8) groups.  A: Raw BP 
trace, B: Mean arterial blood pressure, C: Systolic blood pressure and D: Diastolic blood pressure.   Bars represent mean ± SEM.  One-way ANOVA 
with Bonferroni multicomparison test; *P < 0.05 vs. control values. 
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Table 2.  The effect of HF diet and CIH on baseline cardiorespiratory variables in 
control (n=9), HF (n=8) and HF+CIH groups (n=8). 
  Control HF HF+CIH 
MABP (mmHg) 110±4 122 ± 3 120±3 
SBP (mmHg) 137±4 153±4 * 149±4 
DBP (mmHg) 88±4 97±3 95±3 
HR (bpm) 427±13 438±13 437±9 
Rf  (BPM) 89±3 92±4 89±3 
VT (ml) 1.74±0.08 1.95±0.06 1.93±0.08 
Minute Ventilation 
(ml.min-1) 
154±6 180±10 * 171±3 
FBF (ml.min-1) 2.3(1.4-3) 1.7(0.6-3.6) 3.4(2.2-5.8) ## 
FVR (mmHg.(ml.min-1)-1) 51.7(34.8-88.2) 92.1(33.4-231.7) 38.7(20.1-56.1) # 
Values represent mean ± SEM or (range). One-way ANOVA with Bonferonni multicomparison 
tests,* P <0.05 vs. control and # P<0.05 and ## P <0.01 HF vs. HF+CIH. 
 
 
Figure 9:  Effects of HF diet and CIH on baseline heart rate (bpm) in control (n=9), HF (n=8) and 
HF+CIH (n=8) groups.  Bars represent mean ± SEM.  One-way ANOVA with Bonferroni 
multicomparison tests.
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Figure 10 Effects of HF diet and CIH on haematocrit in control (n=9), HF (n=8) and 
HF+CIH (n=8) groups.   Bars represent mean ± SEM.  One-way ANOVA with 
Bonferroni multicomparison tests. 
 
Baseline Femoral Blood Flow and Femoral Vascular Resistance 
Baseline FBF for control group was 2.3(1.4-3)ml.min-1 (table 2). HF group’s FBF was 
decreased but not significantly (1.7(0.6-3.6)ml.min-1), while HF+CIH groups FBF was 
increased (3.4(2.2-5.8)ml.min-1) but not significantly compared to control group.  HF+CIH 
group’s FBF was significantly increased when compared to HF group. 
Baseline FVR for control was 51.7(34.8-88.2)mmHg.(ml.min-1)-1 (table 2). HF group’s 
baseline FVR was increased (92.1(33.4-231.7)mmHg.(ml.min-1)-1) but not significantly 
compared to control. Baseline FVR for the HF+CIH group was decreased (38.7(20.1-
56.1)mmHg.(ml.min-1)-1) but not significantly compared to control group, however it was 
significantly decreased compared to HF group.  
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Baseline Respiratory Parameters 
Control group had a Rf of 89±3BPM (table 2), with HF and HF+CIH groups also having 
similar frequencies (92±4 and 89±3BPM respectively), no significant difference was found 
between groups (see fig.11A).  VT for control group was 1.74±0.08ml (table 2).  The HF and 
HF+CIH groups VT was ~0.2ml larger (1.95±0.06 and 1.93±0.08ml respectively), but this 
increase is not significant (see fig.11B). 
Control groups minute ventilation was 154±6ml.min-1 (table 2).  HF and HF+CIH both have 
increased minute ventilation (180±10 and 171±3ml.min-1 respectively).  Interestingly the 
increase is significant for the HF (P<0.05), but not HF+CIH group (see fig.11C). 
Normalised minute ventilation was 436±15ml.min-1.kg-1 for control group (table 2).  Both 
HF and HF+CIH groups had minute ventilation per kg ~25ml.min-1.kg-1 lower (408±14 and 
409±9ml.min-1.kg-1), this decrease is not however significant (see fig.11D). 
Growth Curves and Body Mass 
Five week old animals start weights for HF and HF+CIH groups were 222±2 and 222±4g 
respectively.  The HF group showed a linear increase in weight over the 4 weeks HF diet 
(fig.12 A).  The HF+CIH group’s growth curve however shows a change in growth with 
exposure to CIH (fig.12B).  The first 2 weeks on the diet the HF+CIH group’s growth was 
similar to the HF group, but during the final 2 weeks, when exposed to CIH, growth was 
significantly reduced (P < 0.05).  The result of this change in growth meant the HF group 
showed a larger mean increase in weight than the HF+CIH group during the final 2 weeks 
of the diet (see fig.12C). 
  
43 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11:  Baseline ventilation values for control (n=9), HF (n=8) and HF+CIH (n=8) groups.  A: 
Baseline Rf (BPM), B: Baseline VT (ml), C: Baseline minute ventilation (ml.min
-1) and D: Baseline 
normalised minute ventilation (ml.min-1.Kg-1).  Bars represent mean ± SEM.  One-way ANOVA with 
Bonferroni multicomparison tests.  *P < 0.05 vs. control.
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Figure 12: Growth curves (weight, g) from weeks 5-9 for HF (n=8) and HF+CIH (n=8) groups.  A: HF growth curve, B: HF+CIH growth curve and C: Mean growth 
curves for HF and HF+CIH groups.  Values represent individual rat weights with mean ± SEM. 
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Figure 13: Final rat weights (g) for control (n=9), HF (n=8) and HF+CIH (n=8) groups.  
Individual rat weights with mean ± SEM.  One-way ANOVA with Bonferroni 
multicomparison tests; ***P < 0.001, and ****P < 0.001 vs.  control. 
 
Control group animals had a final weight of 353±7g.  The HF and HF+CIH group animals’ 
final weights were significantly heavier than control (440±14 and 418±8g respectively, see 
fig.13).  No significance was found between the HF and HF+CIH group weights. 
Food Consumption 
Food consumption was monitored throughout the HF diet and while animals were in the 
hypoxic chamber.  Rats in the HF group consumed a total of 1887±61g per cage and the 
HF+CIH group 1769±38g per cage. HF groups mean food consumption over the 4 weeks HF 
diet was 22.5±0.7g.day-1 (see fig 14).  HF+CIH group’s food intake was split into the first 2 
weeks HF diet only, and final 2 weeks HF diet with CIH exposure.  The HF+CIH group’s food 
consumption over the first 2 weeks of the diet was 21.8±0.2g.day-1.  During CIH exposure 
HF+CIH group’s food consumption decreased, but not significantly, compared to the first 2 
weeks of the diet. 
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Figure 14:  Mean food consumption (g.day-1) during high fat diet and CIH exposure for HF 
(n=8) and HF+CIH (n=8) groups.  Bars represent mean ± SEM.  One-way ANOVA with 
Bonferroni multicomparison tests. 
Tissue Weights  
All tissues were weighed and normalised per g body weight (table 3).  Tissue weights for 
normal animals were obtained from a previous experimental protocol.  The normalised 
whole heart weight in the normal group was 2.67±0.11mg.g-1.  HF and HF+CIH groups 
normalised whole hearts weights were heavier (3.02±0.06 and 2.78±0.34 mg.g-1 
respectively), though the differences were not significant (see fig.15A). 
Normalised right free wall (RFW) and left free wall (LFW) weights in the normal group were 
0.33±0.07 and 1.11±0.17mg.g-1 respectively (see fig.15B).  The RFW in HF and HF+CIH 
groups were significantly heavier (0.52±0.02 and 0.57±0.02mg.g-1 respectively).  Similarly 
the LFW was also significantly heavier in treatment groups than normal (1.58±0.03 and 
1.50±0.06 mg.g-1 respectively).  No data was available for septum weight in the normal 
group.  Normalised septum weight in the HF group was 0.45±0.03mg.g-1 (see fig.15B).  A 
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Table 3.  Effect of diet and CIH on normalised tissue weight (mg.g-1) in normal (n=6), HF 
(n=8) and HF+CIH groups (n=8).  
  Normal HF HF+CIH 
Whole Heart 2.67±0.10 3.02±0.06 2.78±0.38 
LFW 1.11±0.17 1.58±0.03 ** 1.50±0.06 * 
RFW 0.33±0.72 0.52±0.02 * 0.57±0.02 ** 
Septum N/A 0.45±0.03 0.53±0.03 
Liver 34.38±0.96 38.83±0.89 * 38.71±1.16 * 
PWAT 13.94±2.30 23.38±1.35 ** 22.93±1.87 ** 
EWAT 12.64±0.55 24.41±1.59 **** 20.97±0.82 *** 
Kidney 3.10±0.60 3.77±0.12 4.12±0.24 
EDL 0.41±0.02 0.40±0.02 0.41±0.02 
TA 1.81±0.04 1.62±0.05 * 1.73±0.03 
Soleus 0.46±0.02 0.41±0.01 0.39±0.02 
Values represent mean ± SEM. One-way ANOVA with Bonferonni multicomparison tests,* P 
<0.05, ** P <0.01, *** P <0.001 and **** P <0.0001 vs. control. Normal rat tissue weights were 
obtained from a previous study. 
 
larger septum weight was observed in the HF+CIH group (0.53±0.03 mg.g-1), although no 
significant difference between groups was found. 
Normal normalised liver weight was 34.38±0.96mg.g-1 (see fig.15C).  HF and HF+CIH groups 
had significantly increased liver tissue weights (38.83±0.89 and 38.71±1.16 mg.g-1 
respectively).  PWAT and EWAT normalised tissue weight in the normal group was 
13.94±2.30 and 12.64±0.55mg.g-1 respectively (see fig.15C).  Normalised PWAT weight for 
treated groups were ~ 10mg.g-1 heavier (23.38±1.35 and 22.93±1.87mg.g-1 respectively) 
and were significantly different to normal.  Likewise treated groups normalised EWAT 
weight was significantly larger than normal (24.42±1.59 and 20.97±2.33 mg.g-1 
respectively).  No significant differences were found between HF and HF+CIH treated  
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Figure 15: Effect of HF diet and CIH on tissue weight in normal (n=6), HF (n=8) and HF+CIH (n=8) groups.  Tissue 
weights normalised for body weight (mg.g-1).  A: Whole heart weight, B: Heart weights (normal group septum 
weights were not available and HF group only includes 7) and C: Liver and adipose tissue weights.  Bars 
represent mean ± SEM.  One-way ANOVA with Bonferroni multicomparison tests; *P < 0.05, **P < 0.01, ***P < 
0.001, ****P < 0.0001 vs. control.  Normal rat tissue weights were obtained from a previous study.   
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groups.  Normal groups normalised kidney weight was 3.1±0.60mg.g-1.  HF and HF+CIH 
treatment groups were 3.77±0.12 and 4.12±0.24mg.g-1 respectively. No significant 
difference was found between groups. 
Normalised EDL weight was 0.41±0.02mg.g-1 for normal group with similar weights 
observed in HF and HF+CIH groups (0.40±0.02 and 0.41±0.02mg.g-1 respectively).  Normal 
group’s normalised TA weight was 1.81±0.04mg.g-1.  Both HF and HF+CIH treatment 
groups’ normalised TA weights were lower than the normal group’s (1.62±0.05mg.g-1 and 
1.73±0.03mg.g-1 respectively), although only the HF group was significantly different.  
Normalised Soleus weight was 0.46±0.02mg.g-1 in the normal group, 0.41±0.01mg.g-1 in the 
HF group and 0.39±0.02mg.g-1 in the HF+CIH group.  No significant difference was found 
between groups. 
Glucose Tolerance Test 
Baseline blood glucose in the control group was 7.9±0.5mMol.L-1.  In treatment groups the 
baseline glucose was lower but not significantly in the HF group (6.8±0.3mMol.L-1) and 
significantly lower (P < 0.05) in the HF+CIH groups (6.5±0.3 mMol.L-1).   
All groups had the same size increase in blood glucose at 2 minutes.  The blood glucose 
levels were returned back to baseline levels within 30 minutes of the glucose load in the 
control group (see fig.16A).  The HF and HF+CIH groups both had prolonged elevated 
glucose, and were still above baseline levels 60 minutes after being given the glucose load. 
The total area under the curve (AUC) of the control groups GTT was 140±16.  The two 
treatment groups HF and HF+CIH both had much larger AUCs (183±30 and 206±16 
respectively); however no significance was found between groups (see fig.16B).  
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 Figure 16: Effect of an intravenous glucose load (0.5g.Kg-1) on blood glucose levels in control  
(n=7), HF (n=6) and HF+CIH (n=8) groups.  A: GTT change in blood glucose from baseline 
(mMol.L-1).  B: GTT area under the curve.  Points represent mean ±SEM One-way ANOVA 
with Bonferroni multicomparison tests. 
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Insulin Quantification 
Baseline insulin concentration for control group was 1.2±0.1µg.L-1.  HF and HF+CIH groups 
both had much higher baseline levels (4.8±0.8 and 2.6±0.6µg.L-1 respectively), however 
only the HF group was significant (see fig.18A).  The peak insulin level for control was 
7.58±0.41, both HF and HF+CIH groups had increased values (8.95±0.07 and 8.23±0.37 
µg.L-1 respectively), however only the HF group was significant (see fig.18B).  Control 
group’s insulin returned to baseline level within 30 minutes (see fig.17 and fig.18C), 
conversely HF and HF+CIH groups insulin was still elevated after 60 minutes.  The AUC for 
control groups was 176±5 (see fig.18D); significantly larger AUCs were found in the HF and 
HF+CIH groups (437±24 and 360±20 respectively). 
 
 
 
 
 
 
 
 Figure 17:  Effect of an intravenous glucose load (0.5g.kg-1) on serum insulin levels in 
control (n=4), HF (n=5) and HF+CIH groups (n=3).  Points represent mean ± SEM. 
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Figure 18:  Effect of GTT on serum insulin levels for control (n=4), HF (n=5) and HF+CIH (n=3).  A: Baseline insulin (µg.L-1), B: Peak insulin (µg.L-1), C: End insulin (µg.L-1) and 
D: Insulin AUC.  Bars represent mean±SEM.  One-way ANOVA with Bonferroni multicomparison tests; * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001 vs control. 
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GTT Respiratory Parameters 
Control groups baseline Rf was 91±6BPM.  HF and HF+CIH both had similar baseline Rf 93±5 
and 89±3BPM respectively.  All groups Rf was increased at 2 minutes, although only the 
HF+CIH group was significant.  Control and HF+CIH groups Rf returned back to baseline by 
30 minutes, however the HF groups Rf remained elevated (see fig.19A). 
Baseline VT in the control group was 1.82±0.06ml and did not change throughout the GTT.  
HF and HF+CIH groups’ baseline VT were 2.00±0.08 and 1.96±0.08ml respectively, with 
both groups VT increasing over the test.  The HF group was significantly increased at 60 
minutes and the HF+CIH group was significantly at 30 and 60 minutes (see fig.19B). 
Baseline minute ventilation in control group was 165±10ml.min-1.  HF and HF+CIH both had 
slightly higher baseline minute ventilations 185±11 and 173±3 ml.min-1 respectively.  All 
groups minute ventilation was increased at 2 minutes but only the HF+CIH groups increase 
was significant (see fig.19C).  Control groups minute ventilation then returned to baseline, 
whereas the treatment groups remained elevated with both significantly increased at 60 
minutes (see fig.19C). 
Dejours Test Respiratory Parameters 
The control groups Rf decreased significantly from baseline during the Dejours test.  The HF 
and HF+CIH groups also decreased significantly from their baselines during the test, with 
all three groups decrease ~20BPM in magnitude (see fig.21A).  No significant difference 
was found between groups Rf at baseline (see fig.20A). 
VT was not altered from baseline during the Dejours test for the control group.  The HF and 
HF+CIH groups VT also did not appear to be affected by application of the Dejours test.  No 
significant difference was found between individual groups’ baseline and Dejours  VT  
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Figure 19: Effect of intravenous glucose load (0.5g.Kg-1) on ventilation in control (n=7), HF (n=6) and 
HF+CIH (n=8) groups.  A: ∆Rf (BPM), B: ∆VT (ml) and C: ∆ minute ventilation (ml.min
-1).  Bars represent 
mean ± SEM.  One-way ANOVA with Bonferroni multicomparison tests; # P < 0.05, ## P < 0.01 HF vs HF 
baseline, † P < 0.05, †† P < 0.01 and ††† P < 0.001 HF+CIH vs HF+CIH baseline. 
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values, there was however a significant difference between the control and HF+CIH groups 
baseline VT (see fig.20B). 
The control group’s minute ventilation at baseline was lower than the HF and HF+CIH 
group’s minute ventilation.  However only the HF+CIH groups baseline minute ventilation 
was significantly increased (see fig.20C).  The control group’s minute ventilation 
significantly decreased with application of the Dejours test.  Significant decreases were 
also observed in the treatment groups during test application (see fig.21B).  The decrease 
in minute ventilation in the control group was 36±5ml.min-1.   HF and HF+CIH both had 
larger decreases in minute ventilation (42±5 and 49±3ml.min-1 respectively), however 
neither decrease was significant compared to control (see fig.21B). 
Normalised minute ventilation decreased significantly with application of the Dejours test 
in all groups (P < 0.0001, P < 0.001 and P < 0.0001 respectively).  No significant difference 
was found between groups’ baseline normalised minute ventilations (see fig.20D). 
Sympathetic Chain Stimulation 
Sympathetic chain stimulation at 20Hz produced an increase in control group FVR of 30±4 
mmHg.(ml.min-1)-1.  The increase in HF and HF+CIH groups FVR during 20Hz stimulation 
was slightly less (25±7 and 27±7mmHg.(ml.min-1)-1respectively), with no significance found 
between groups (see fig.22A). 
2Hz stimulation caused a much smaller increase in FVR with control group only increasing 
by 5.6±0.9 mmHg.ml-1.min.  A slightly smaller increase was also seen in the HF group 
(3.7±1.7 mmHg.(ml.min-1)-1).  The increase produced in the HF+CIH group however is twice   
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Figure 20:  Effects of the Dejours test (100% O2) on ventilation in control (n=9), HF (n=8) and HF+CIH 
(n=8) groups.  A: Rf (BPM), B: VT (ml), C: Minute Ventilation (ml.min
-1) and D: Normalised minute 
ventilation (ml.min-1.Kg-1).  Bars represent mean ± SEM.  One-way ANOVA with Bonferroni 
multicomparison tests compare baseline values; *P < 0.05 vs control. 
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Figure 21: Effects of the Dejours test (100% O2) on ventilation in control (n=9), HF (n=8) and 
HF+CIH (n=8) groups.  A: Change in Rf from baseline (BPM) and B: Change in minute 
ventilation from baseline (ml.min-1).  Bars represent mean ± SEM.  Students t test between 
baseline and 100% O2 values; ***P < 0.001, ****P < 0.0001 control, ###P < 0.001 HF and 
††††P < 0.0001 HF+CIH groups.  One-way ANOVA with Bonferroni multicomparison tests. 
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as large (10.5±2.1 mmHg.(ml.min-1)-1) but was only significantly different to the HF group 
(see fig.22B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22:  Effects of sympathetic chain stimulation on femoral vascular resistance 
(mmHg.(ml.min-1)-1)in control (n=5), HF (n=4) and HF+CIH (n=5) groups: A.  Sympathetic 
Stimulation 20Hz; B.  Sympathetic Stimulation 2Hz. Bars represent mean ± SEM.  One-way 
ANOVA with Bonferroni multicomparison tests; † P < 0.05 HF vs.  HF+CIH. 
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DISCUSSION 
Overview 
We aimed to examine the combined effects of HF diet and CIH on cardiorespiratory 
parameters, glucoregulation, CB activity and sympathetic tone. Our findings show HF diet 
generates obesity as increases in body weight; PWAT and EWAT were observed, with CIH 
tending to reduce weight gain on HF diet. HF diet also caused a significant increase in SBP 
which contributed to the tendency for MABP to be increased by 12±3mmHg. The addition 
of CIH resulted in MABP tending to be increased by 10±3mmHg, with SBP not significantly 
increased. IR and ventricular hypertrophy were both caused by HF diet, with CIH not 
affecting IR or hypertrophy. Findings present no evidence of increased CB activity or 
sympathetic tone which do not appear to be altered by HF diet or CIH. 
Blood Pressure and Heart Rate 
As both HF diet and CIH have been reported to cause HT we hypothesised that HF diet and 
CIH would result in a more severe HT than HF diet alone. Baseline MABP showed a 
tendency to be increased in treatment groups although not significantly. SBP and DBP also 
showed a tendency to be increased in treatment groups; with the HF groups SBP 
significantly higher. 
Comparing these finding to the literature, showed that other studies which used the HF 
diet model reported MABP significantly greater than their controls. Ribeiro et al (2013) 
reported MABPs of 96±3mmHg in control and 142±2mmHg in animals fed a high fat diet. 
These values differ considerably from the findings of this study. Ribeiro et al (2013) 
attribute the HF diet induced HT to increased CB activity as CSN resection prevented 
arterial pressure increase. They dismissed any baroreceptor mediated effect, which also 
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transmits information via the CSN, stating rats would have become hypertensive after CSN 
denervation (Ribeiro et al 2013).  
Firstly Ribeiro’s control groups MABP is much lower than the 110±4mmHg found in this 
study. A possible explanation of this may be the difference in anaesthesia used in the 
studies. Most anaesthetics cause a reduction of BP in rats, with the haemodynamic 
changes dependent on the type of anaesthetic used (Bencze et al 2013). Ribeiro used 
intraperitoneal injection of sodium pentobarbital whereas IV Alfaxan (alfaxalone) was used 
in this study. Pentobarbital anaesthesia is known to lower CO and decrease systemic 
vascular resistance resulting in BP decrease (Bencze et al 2013). Alfaxan has been shown to 
cause minimal changes in cardiovascular variables, with no change in CO and only a small 
decrease in systemic vascular resistance resulting in minor decreases in BP (Muir et al 
2009). 
Secondly the difference observed between MABP in HF diet fed rats, may be down to a 
number of reasons. Time spent on the diet may affect MABP. Ribeiro fed rats HF diet for 21 
days, which was less than the 4 weeks diet used in this study. As HF diet is a model of HT, it 
would be expected the longer spent on the diet to result in a greater increase in MABP, 
although this was not the case. Therefore a possible explanation is the actual composition 
of the HF diet itself. Ribeiro states the HF diet used was 45% fat, 35% carbohydrate and 
20% protein, however it was not clear if this was the diet composition or where animal’s 
calories are derived from. The diet used in this study contained 21% fat by composition but 
42% of calories were derived from fat. This potentially considerable difference in dietary 
fat content could be an explanation of why MABP was so much higher in Ribeiro’s study 
even though they spend less time on the diet. Rat’s age is also a possible explanation for 
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differences in MABP. The rats in our study were 9 weeks old when experiments were 
performed. In Ribeiro’s study rats were 3 months old, 3 weeks older than this study. Older 
rats may be more susceptible to HF diet induced HT than younger rats. 
An explanation for the increased SBP could be increased sympathetic activity to the heart. 
The sympathetic NS innervates the heart at the SA and AV nodes as well as innervating 
throughout the myocardium. Increased sympathetic activity to the ventricular myocardium 
would increase their contractility and thereby explain the observed increases in SBP.  
In agreement with this was the observed tendency for HR to be increased, although not 
significantly, in treatment groups. As already stated the sympathetic NS acts at the SA 
node, the hearts pacemaker. An increase in sympathetic activity results in an increased 
rate of SA node discharge, increasing HR. 
The tendency for DBP to be increased could also be explained by increased sympathetic 
activity. DBP is increased with a sympathetic mediated increase in HR, as well as any 
increase in sympathetic NA causing increased tonic constriction of blood vessels (Fisher 
and Paton 2012). 
Although these results did not indicate HF diet induced HT, they do appear to suggest 
animals BP was moving in that direction, as they showed a tendency to be increased. It is 
possible that increasing the length of time on the HF diet or increasing the diet’s fat 
content further may result in animals becoming hypertensive.  
The findings did not support what was initially proposed. The addition of CIH on top of HF 
diet did not result in a larger BP increase. If anything the addition of CIH had a tendency to 
lessen the BP increase, however difference between the HF and HF+CIH group were not 
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significant. The absence of a CIH only group means determining the effect of this CIH 
protocol on BP is difficult. Fletcher et al (1992a) reported elevated BP from CIH alone, 
accrediting the elevation to increased CB activity as the elevation was prevented by CSN 
resection. In a further experiment by Fletcher (1992b), he showed that the peripheral 
sympathetic NS is necessary for the persistent BP increase associated with CIH. 
As both HF and CIH appear to elevate BP by activating the CB, It poses the question why 
the effects were not additive. It is possible that as the CB was already activated by HF diet 
the addition of the CIH on top did not result in any greater stimulation, therefore did not 
cause an additional increase in BP.  
Another potential explanation of why treatment group’s BP lacks significance could be due 
to the study possibly being underpowered and failing to detect an effect that actually 
existed. The time constraints of an 18 week project meant it was not possible to get equal 
numbers of animals in each group therefore control (9 animals) has more than the 
treatment groups (8 animals each). As increasing the sample size is the easiest way to 
boost statistical power. If more time was available increasing these treatment group 
numbers could possibly result in the data becoming statistically significant as BPs are 
already close to being significantly increased. 
Heart Tissue Weights  
Animal hearts were removed and weighed (including atria), before being separated into 
the LFW, RFW and septum. Whole heart weights were not significantly altered in 
treatment groups although there was a tendency to be increased, with the effect more 
pronounced in the HF group. 
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Although whole heart weights were not significantly increased, treatment groups LFW and 
RFW weights were, suggesting hypertrophy of the ventricles. These findings agree with 
what was expected and are associated to the tendency of BP and HR to be increased.  The 
increase in BP is potentially caused by sympathetic mediated increase in TPR, which has 
been correlated to increased LV wall thickness (Devereux et al 1987).  Increased TPR 
causes the heart to pump against an increased pressure load and results in LV hypertrophy, 
as an adaptation to maintain normal wall stress levels , as increased pressure can be offset 
by an increase in wall thickness( Devereux et al 1987, Ganau et al 1992, Lorell and 
Carabello 2000). 
The LV hypertrophy could also be explained by increased sympathetic NA to the heart, 
which would agree with the tendency for HR to be elevated in treatment groups.  
Increased sympathetic activity would increase HR and CO, consequently the increased 
workload would cause ventricular hypertrophy. 
Increased RV mass associated with obesity is thought to be due to increased CO and 
increased pulmonary vascular resistance and artery pressure which lead to increased RV 
afterload and hypertrophy (Her et al 2006).  OSA has also been associated to RV 
hypertrophy due to hypoxic pulmonary vasoconstriction (HPV) and pulmonary vascular 
remodelling. In the presence of hypoxia, pulmonary arteries constrict, redirecting blood 
flow to alveoli with higher oxygen content, causing pulmonary HT (Welsh and Peacock 
2013). OSA patients have pulmonary hypertension in the daytime as well when they are 
not apnoeic suggesting other complex physiological and structural factors are involved and 
it is not just down to HPV (Welsh and Peacock 2013). Hypoxia is also known to cause an 
increase in pulmonary vascular cell proliferation, by inhibiting antimitogenic factors and 
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production and release of mitogenic stimuli such as endothelin-1, VEGF and inflammatory 
mediators (Welsh and Peacock 2013). The increased cell proliferation results in pulmonary 
vascular remodelling increasing resistance due to vascular wall thickening that reduces the 
size of the vessel lumen. Both HPV and pulmonary vascular remodelling would cause 
increased vascular resistance forcing the heart to work harder, and result in hypertrophy of 
the right ventricle. 
Treatment group septum weights were not different from each other; however normal 
group weights were unavailable. It is therefore not possible to conclude if mass was 
increased in treatment groups although it would be expected. The septum splits the left 
and right ventricles but functionally is more part of the left ventricle (Myslinski et al 2007). 
As left ventricle mass was increased it would be expected the same mechanisms would 
increase septum mass. 
The addition of CIH to HF diet did not seem to have any effect on heart tissue mass, this 
agrees with what was reported by Niroumaud et al (2001) that LV mass is increased in OSA 
only due to patient’s associated obesity, aging and HT.  However the lack of a CIH only 
group means we cannot confirm that this CIH protocol had no effect on heart tissue mass. 
Haematocrit  
No alterations in haematocrit were observed, with treatment groups having nearly 
identical haematocrit values as control. This observation suggests neither HF diet nor the 
addition of CIH had any effect on the volume of red blood cells in the blood. 
Obesity is a known inflammatory condition. Inflammation is known to have a role in 
suppressing erythropoiesis, so haematocrit value could be expected to decrease with HF 
diet (Vuong et al 2014). However in humans haematocrit has been shown to be positively 
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correlated to waist circumference, a known correlate of obesity (Vuong et al 2014). This is 
also supported by increased erythropoiesis in spite of the effects of inflammation in 
metabolic syndrome patients. The possible explanation being increased insulin levels, as 
there is evidence insulin and insulin like growth factors enhance erythropoiesis (Vuong et 
al 2014).  
Previous studies have reported mixed findings with regard to the effect of CIH on 
haematocrit. Studies by Fletcher et al (1992a and 2000) found CIH exposure (2 per minute, 
8 hours per day over 40 days) caused no change in haematocrit or only a tendency to 
increase without being significant. McGuire and Bradford (2001) however report significant 
increase in haematocrit with exposure to CIH (2 per minute, 8 hours per day over 25 days). 
Comparing these studies with the CIH treatment we used, showed a similar duration (8 
hours) and a similar length (28 days) as that of McGuire’s study. This study however used a 
much lower frequency of hypoxias 6 per hour. Therefore if increasing haematocrit is one of 
the body’s mechanisms for dealing with CIH, as it is known to be for chronic hypoxia 
(McGuire and Bradford 2001), then this adaptation would likely be occurring at a much 
greater rate with the increased frequency of hypoxias in Fletcher and McGuire’s studies. 
The CIH model used in this study is over the threshold for diagnosis yet under the level 
required for treatment so can be thought of as an early stage development model, so 
would not necessarily show this adaptation. 
As haematocrit was not altered throughout this study we expected normal O2 delivery was 
taking place during normoxic conditions. However the absence of increased red blood cell 
numbers may be detrimental during periods of IH, and animals may not have be able to 
maintain the same level of O2 delivery. 
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Baseline Respiratory Parameters 
Based on the literature which shows both HF diet and CIH stimulate the CBs, we 
hypothesised that baseline respiratory parameters would be increased in HF diet fed 
animals, and the addition of CIH would further augment the increase.  
No difference in baseline Rf was observed between groups, therefore providing no 
evidence of increased CB drive in treatment groups. This finding does not match what has 
been previously reported in the literature. Ribeiro et al (2013) observed increases in all 
spontaneous ventilatory parameters (Rf, VT and minute ventilation) with application of a HF 
diet. They proposed the effect was mediated by overstimulation of the CBs, as surgical cut 
of CSN completely abolished the diet induced increase in spontaneous ventilation. Again 
these differences may be explained by differences, as previously stated, in HF diet 
composition with Ribeiro’s study possibly using a diet containing more than twice as much 
fat as the diet used in this study.  
Minute ventilation is the product of Rf and VT and was increased in both treatment groups, 
significantly in the case of the HF group. These increases in minute ventilation can be put 
down to VT, as it was increased but not significantly in treatment groups, and Rf remained 
unaltered. Ventilation is matched to metabolism, so an increased VT indicates an increase 
in metabolism and CO2 production in treatment groups.  
When body weight was taken into account with minute ventilation, it showed the control 
group’s minute ventilation was higher than the treatment groups. The disappearance of 
the significance between control and HF group’s normalised minute ventilation may 
suggest that the significantly larger minute ventilation was purely down to the size of the 
animals, with HF group rats considerably heavier than the control group. No additional 
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increase in ventilation with application of CIH is observed and provides no evidence of 
augmented CB activity.  
Growth, Body Mass and Food Consumption 
The final weights of treatment groups were significantly larger than control animals, which 
was expected as HF diets are a model of obesity and previous studies have shown 
increased weight gain (Ribeiro et al 2013). 
The addition of CIH on to a HF diet caused a significant reduction in animal’s growth which 
ultimately explains the difference observed in final weights. This difference was attributed 
to CIH as during the two weeks prior to the introduction of CIH animal’s growth, on HF diet 
alone, was very similar to the HF group. Growth was only significantly altered between 
groups during the CIH exposure in the final two weeks of HF diet. 
Animals’ food consumption data showed the HF+CIH groups food intake was decreased, 
although not significantly, during CIH exposure by approximately 1.5g.day-1.  This reduced 
intake explains the observed reduction in growth during CIH exposure, and ~20g difference 
in final weights between HF and HF+CIH groups. 
Crossland et al (2013) found no effect of CIH on growth or food intake. However Fletcher 
et al (1992b) and also Olea et al (2014) report CIH decreased growth in normal and HF diet 
fed rats, which agree with our findings. The different results may be explained by the 
different rat strains used; Crossland used Long Evans rats which may respond to CIH 
differently to the Wistar used in the other studies. Length of CIH exposure may also explain 
the different results, with rats exposed much longer than the 4 weeks Crossland used. 
Although this study only used 2 weeks CIH exposure, the results could be explained by the 
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HF diet used in this study, which may have exacerbated growth differences due to 
increased weight gain. 
Tissue weights 
Feeding rats a HF diet is a model of obesity, we therefore hypothesised that there would 
be increased amounts of fat in rats fed HF diet. There were significant increases in liver, 
PWAT and EWAT tissue weights in treatment groups, which were expected as a result of 
the HF diet. 
The PWAT, EWAT and liver are known sites of fat deposition; however the kidney is not, so 
can be used as an estimate of lean body mass. Comparing kidney weights showed no 
significant increases in treatment groups, indicating HF diet has not affected lean body 
mass. From this the assumption can be made that the increased final weights of treatment 
groups’ was predominantly down to the increases in fat stores, therefore indicating obesity 
was present.  
The addition of CIH to HF diet did not seem to have any effect on adipose and liver tissue 
weights as no differences were observed when compared to the HF diet only group. These 
results agreed with Olea et al (2014), who reported significantly larger EWAT and PWAT 
weights in HF diet fed animals and found no difference in fat pad weight in animals also 
exposed to CIH (Olea et al 2014). The observation that treatment group livers had a 
discoloured appearance and the significant increase in mass suggest HF diet may have 
resulted in development of non-alcoholic fatty liver disease.  
The HF group showed a significant decrease in normalised TA muscle mass and a tendency 
for normalised soleus muscle mass to be decreased. The HF+CIH group also showed a 
tendency for decreased normalised TA and soleus muscle masses. No change in normalised 
69 
EDL mass was observed between groups. Looking at groups’ actual muscle mass values 
(appendix table 4) revealed there are no significant differences between groups, 
suggesting animals’ have the same lean body mass.  Therefore the decrease in normalised 
muscle mass is due to the extra body mass, which is most likely to be fat, of treatment 
groups and not a reduction in the actual muscle mass. 
This tendency for decreased normalised muscle mass and same lean body mass suggests 
treatment group animals do not exercise as much.  This however cannot be confirmed as 
no measures of animals’ activity were made.  The HF+CIH group did not show the same 
decrease in normalised mass as the HF group, this possibly could be explained by the 
reduced obesity of the HF+CIH group compared to the HF group.  Alternatively it could be 
explained by exposure to hypoxia, which may cause excitation of animals and an increase 
in exercise. 
GTT and Insulin Levels 
IR is known to be associated with obesity and it has also been linked to IH. We therefore 
hypothesised that feeding rats a HF diet would result in IR and altered blood glucose 
profiles, with the addition of CIH causing these effects to a greater degree.   
Baseline fasting blood glucose showed a tendency to be higher in control group than HF 
group and was significantly higher than HF+CIH group. Baseline fasting glucose levels 
appear high as previous results from this lab have found baseline levels to be around 
4.6mmol.L-1, which is similar to the 4.1mmol.L-1 reported by Olea et al (2014). Other 
studies report slightly higher control group glucose levels ~6mmol.L-1 (Nagarajan et al 
2013, Yokoe et al 2008), but they are still lower than found in this study. A simple 
explanation for this difference could be due to surgical trauma. The control group 
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experiments were the first set to be completed and as such were done during a learning 
period of surgical skills and technique.  This resulted in control group animals being 
anaesthetised for a much longer periods and undergoing more traumatic surgery than HF 
and HF+CIH groups. Unfortunately due to the time pressures associated with an 18 week 
project it was not possible to repeat the control group to definitively determine if the 
higher baseline was a result of traumatic surgery.  To avoid the effect of the traumatic 
surgery in future experiments a tail prick sample immediately before surgery would allow 
accurate measurement of baseline glucose. 
Two studies (Nagarajan et al 2013, Olea et al 2014) both reports HF diet increases fasting 
glucose levels. This does not agree with our results, but may be due to the elevated 
appearance of control group glucose levels. 
Olea (2014) and He (2014) both showed hypoxia increased blood glucose and insulin levels. 
Olea (2014) also found the combination of CIH and HF diet to significantly increase blood 
glucose, but it was not significantly higher than HF diet alone.  Again these results do not 
agree with our findings but may be due to increased glucose levels in control group. 
As expected the blood glucose levels increased with administration of the IV glucose dose 
and evoked the same size change in all groups.  However that was where similarities 
between control and treatment groups blood glucose profile stopped.  Control group 
blood glucose was returned to baseline levels by 30 minutes, whereas HF and HF+CIH 
groups had not recovered and blood glucose was still elevated after 60 minutes.  The 
differences in these profiles was clearly shown by the AUC with both treatment groups 
having a tendency to be increased although not significantly.  
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Baseline insulin levels were significantly elevated in HF group and HF+CIH also showed a 
tendency to be increased.  This suggests altered glucose handling, with larger quantities of 
insulin required to maintain blood glucose at resting levels due to IR. The significant 
increase in baseline insulin with HF diet agrees with Olea et al (2014), however they also 
showed when combined with IH it causes a further increase in baseline levels.  
IR was expected with the HF diet known to result in altered insulin sensitivity.  The insulin 
curve matched the GTT curve, with both increased at 2 minutes and lower at 60 minutes.  
Although groups were given the same glucose dose each group produced different changes 
in insulin.  The peak insulin levels were at similar values, even though the HF group 
baseline was significantly higher statistically than control.  This points to a maximum 
insulin output with HF and HF+CIH basal insulin levels reducing the amount of increase 
possible. 
The insulin AUC was significantly larger than control showing insulin levels were raised for 
longer. This agrees with the GTT, as glucose levels were still raised after an hour.  Failure to 
return to baseline levels within an hour points towards altered glucose handling ability and 
IR, which was expected to occur with the HF diet.  The absence of any significant difference 
between HF and HF+CIH groups suggests no additional detrimental effects on glucose 
handling or increased IR were caused by CIH. 
GTT Respiratory Parameters 
Glycaemic level and insulin have both been proposed as CB stimulators; therefore 
alterations in ventilation during GTT due to CB activation were expected.  All groups 
showed a trend of increased ventilation at 2 minutes of the GTT; however treatment 
groups remained elevated over the rest of the GTT and control returned to baseline.  This 
72 
effect could possibly be explained by increased CB activity, as change in Rf was the cause of 
the increased ventilation.  The effect may be driven by glucose or insulin.  As both were 
increased at 2 minutes and returned to baseline with control group’s ventilation.  Both also 
stayed elevated in treatment groups past 30 minutes where ventilation remained elevated. 
Glucose has been put forward as a stimulator of the CB, with both Hypo- and 
hyperglycaemia showing increases in ventilation and augmentation of HVR (Limberg et al 
2014, Ward et al 2007).  Insulin has also been proposed as a direct trigger of the CBs, 
capable of initiating a neurosecretory response that is transduced into an increase in 
ventilation (Ribeiro et al 2013).  The continued elevation of ventilation in treatments 
groups as glucose and insulin levels were falling points towards an increased sensitivity 
rather than just an increase in tonic baseline activity.  This agrees with the observed slow 
increase in HVR with hyperglycaemia, and its persistence even with return to euglycaemia 
could imply a slow modification of hypoxic sensing mechanisms by glucose (Ward et al 
2007).  However due to the lack of blood gas data, hypoxia and hypercapnia cannot be 
ruled out as causes of the ventilatory changes. 
Dejours Test 
Inhalation of hyperoxia (Dejours test) suppresses CB drive, therefore the magnitude of 
ventilatory depression caused by O2 can be used as an index of CB activation. HF diet and 
CIH have been shown to stimulate the CB. We therefore hypothesised CB activity would be 
increased in HF diet, with further augmentation when combined with CIH.  
The significant baseline minute ventilation increase in HF+CIH and elevated tendency in HF 
groups can be explained by the increased VT in treatment groups, as no difference in Rf was 
seen between groups. No significant differences between minute ventilation were 
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observed when it is normalised for body weight suggesting these increases may be due to 
increased animal size. 
All respiratory parameters except VT significantly decreased with application of 100% O2 as 
expected. The size of the decreases in Rf was the same for all groups and there was no 
significant difference in minute ventilation decreases. This along with the similar R f 
baseline values indicates no CB over activity in treatment groups. This was not what was 
expected, with increased baseline Rf and larger ventilatory depressions in HF group with 
further augmentations when combined with CIH. 
Baseline FBF and FVR 
Baseline FBF showed a tendency to be decreased in the HF group, although not 
significantly. The HF group also had a significantly reduced normalised TA mass, and a 
tendency for soleus normalised mass to be decreased. No change in normalised EDL mass 
was observed. This suggests that the differences in muscle mass can explain the observed 
differences in FBF, as a higher blood flow would be expected to larger muscles. 
The HF+CIH group data did not agree with the HF group. The HF+CIH group showed a non-
significant tendency for increased FBF, but tendency for decreased TA and soleus 
normalised muscle masses, and no change in normalised EDL mass.  Therefore FBF 
differences cannot be explained by differences in leg muscle masses. 
One possible explanation for the tendency for raised BP would be an increase in TPR and 
the trend in FVR is consistent with this. The tendency for FVR to be decreased in the 
HF+CIH group however does not agree with this as HF+CIH group also showed a tendency 
for BP to be increased. Instead the HF+CIH groups BP may be explained by a specific 
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increase in cardiac sympathetic activity, with no change in muscle sympathetic activity 
causing the tendency for BP to be elevated. 
There are however concerns over the baseline FVR values, due to variation in baseline FBF 
within groups.  The instrument is the likely cause of variation observed within groups and 
therefore comparisons between groups baseline values cannot be confidently made.  The 
linearity of the changes from baseline however did appear to be consistent and so can be 
used for comparison.  This means it is not possible to conclude definitively that TPR is 
altered in treatment groups. 
Sympathetic Stimulation 
Vasoconstriction is a major mechanism in the development of HT, which could be 
mediated by sympathetic NS.  Alternatively it may be due to increased endothelial 
vasoconstrictors or decreased vasodilators, but due to time constraints we cannot assess 
all these effects.  Therefore we hypothesised that animals fed HF diet would show 
increased levels of sympathetic output, which would be further increased by the addition 
of CIH.  
Sympathetic chain stimulation at 20Hz resulted in larger FVR increases than stimulation at 
2Hz.  The 20Hz stimulation evoked similar increases in FVR in all groups; 2Hz stimulation 
evoked similar FVR increases in control and HF groups but caused a larger increase in the 
HF+CIH group.  The HF+CIH group FVR increase was significantly larger than the HF group; 
however this is not an accurate representation as the difference was not actually 
significant.  In the HF group the 2Hz stimulation did not work on one animal, yet the 20Hz 
stimulation did.  Unfortunately this is a limitation in the nature of this type of stimulation.  
Therefore in order to keep the 20Hz stimulation in the results, as n numbers were quite 
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low, the animal was not excluded. Due to the inclusion of this result it has reduced the 
mean FVR and also resulted in a statistical significance between the HF and HF+CIH groups. 
Exclusion of this value (see appendix fig 23) increased the HF group mean to 
5.2±1.2mmHg.(ml.min-1)-1 and resulted in loss of significance when compared to the 
HF+CIH group. 
The same FVR response was evoked by 20Hz stimulation in all groups and no real 
significant difference in 2Hz stimulation responses point towards no increase in tonic 
sympathetic activity in HF or HF+CIH groups. This does not agree with the literature. Olea 
et al (2014) measured plasma catecholamine levels, another indirect measure of 
sympathetic activity, showing increases in noradrenaline and adrenaline levels with HF diet 
and CIH.  Concluding sympathetic activity is increased and proposed it was mediated by 
the CB in CIH, and obesity causing activation by leptin with the CBs also contributing. 
Concerns over the variability observed in baseline FBF and FVR values would not have 
affected the sympathetic evoked changes in FVR results. Peak values from the baseline 
immediately before each stimulation were taken, therefore variations in the baseline level 
within groups would have no effect on the magnitude of the FVR change, which appeared 
consistent within groups. 
Study Limitations 
Insulin quantification was done using a rat specific insulin ELISA, however absorbance 
readings given were outside the calibration curve range. Insulin values therefore had to be 
extrapolated beyond the calibration curve using a non-linear regression curve. Although 
this curve did fit it was not the curve recommended by the manufacturer for interpolation 
of insulin content. Cubic spline regression was recommended however this did not allow 
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for extrapolation of results beyond the calibration curve range. Values that fell within the 
calibration curve were interpolated and compared using both non-linear and cubic spline 
regression which showed similar values. However extrapolated values may not be as 
accurate due to insulin’s absorbance not continuing exactly on the extended curve. 
Repetition of insulin quantification was not however possible due to time and ELISA cost. 
In future extrapolations may be avoided by dilutions of serum samples before insulin 
quantification. 
A limitation in the design of this study was the absence of a CIH only group. Unfortunately 
due to the time constraints it was not possible to fit an additional group fed standard rat 
chow and exposed to CIH for 2 weeks.  In future studies the inclusion of a CIH only group 
would make the effects of the CIH protocol clearer than when it is in combination with 
other treatments. 
The lack of blood gas analysis is also a limitation of this study. Inclusion in future projects 
would enable hypoxia and hypercapnia to be ruled out as the cause of any ventilatory 
changes, as well as provide information about the activity of the metabolic system (Burns 
2014). 
The food and water intake of HF and HF+CIH groups was monitored throughout the 4 week 
diets.  However there were some issues with the monitoring. Animals were housed in 
BMSU with staff checking them every day. As such if rat’s water was getting low they 
would refill the bottle, however would not record the amount of water left before refilling, 
only the amount they had filled to. Another issue was they would not always record the 
date they had refilled which caused problems when calculating intake. These problems 
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could be avoided by monitoring the animals on a daily basis, instead of the twice weekly, 
as this would ensure water does not become low and consumption recorded properly. 
Another limitation is that control group animal’s growth and intake over the 4 weeks on 
standard diet was not monitored.  Animals were bought in at the correct age for 
experiments due to time implications.  Ideally all animals would have been obtained at the 
same age (5 weeks) and kept in BMSU over the duration of the diets. 
There are various limitations involved with the method of sympathetic stimulation used.  
Firstly the response elicited by this technique is not always an increase in FVR, no response 
or occasionally a negative response are observed, and because of this n numbers are lower 
than other parts of the protocol. The absence of some responses may be explained by 
placement of electrodes.  Electrodes were fixed in place with silicon, however if they 
moved during set up and touched or became surrounded by fluid it could cause them to 
short out. Constant voltage stimulation was used in this study, this method results in more 
variable FVR responses. Alternatively constant current stimulation could be used as it 
evokes more consistent responses; however a constant current stimulator was not 
available for this project. Substitute methods that could be used instead of sympathetic 
stimulation are plasma and urine catecholamine level quantification or muscle sympathetic 
nerve activity recording both of which would provide accurate measures of sympathetic 
activity. 
A major unavoidable limitation of this project was the surgery itself.  At the start of the 
project there was a major learning curve of surgical skills. As such animals that were 
experimented on at the start of the project underwent a lot more trauma and spent longer 
under anaesthesia than those at the end of the project. Control animals were the first 
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group experimented on; therefore any effects of the surgery may have effects on the 
significance of findings when comparing with the treatment groups. This could be avoided 
in future by surgery being conducted by a competent experimenter, where surgery trauma 
is not going to vary dramatically. Alternatively it could be avoided by mixing up the order 
animals are experimented on. This was not possible due to the time restraints of this 
project, as the HF and HF+CIH animals take longer to develop than control group. If more 
time was available further control group experiments could be done to determine the 
effects of traumatic surgery on results such as baseline glucose levels. 
Conclusions 
In conclusion, 4 weeks HF diet induced obesity, IR and ventricular hypertrophy. HF diet also 
caused a significant increase in SBP, which contributed to the tendency of MABP to be 
increased by 12±3mmHg. In combination with CIH, there was a reduction in weight gain, 
but no effect on IR or hypertrophy. MABP tended to be increased by 10±3mmHg, and SBP 
was not significantly increased. The absence of altered ventilation and augmented 
response to hyperoxic challenge both suggest no increase in CB activity was caused by HF 
diet or CIH. Also results provide no evidence HF diet or CIH caused increased sympathetic 
output. 
The tendency for increased BP and the ventricular hypertrophy suggest this low AHI model 
did produce cardiovascular changes. However these changes may be on different time 
scales and with longer exposure rats may have developed significant increase in MABP. 
Therefore this could possibly be thought of as an early stage development model of OSA. 
As alteration of glucose homeostasis and cardiovascular changes are observed with this 
model it may indicate that OSA should be targeted for treatment earlier. Allowing the use 
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of less radical treatment methods, such as weight loss and glycaemic control, to prevent 
OSA developing further.  
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APPENDIX 
 
Figure 23:  Effect of 2Hz sympathetic chain stimulation on femoral vascular resistance (mmHg.(ml.min-
1)-1) in control (n=5), HF (n=3) and HF+CIH (n=5) groups.  Bars represent mean ±SEM.  One-way 
ANOVA with Bonferroni multicomparison tests. 
  
 
Table 4: Effect of diet and CIH on muscle tissue weight (mg) in normal 
(n=6), HF (n=8) and HF+CIH groups (n=8).  
 Normal HF HF+CIH 
EDL 147±8 175±10 171±9 
TA 653±19 714±36 719±9 
Soleus 166±7 182±9 162±8 
Values represent mean ± SEM. One-way ANOVA with Bonferonni multicomparison 
tests. Normal rat tissue weights were obtained from a previous study. 
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